AbCellera Biologics Inc. (ABCL) P/E Ratio History
Deep ValueTrading at -11.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2022
Loading P/E history...
P/E Ratio Analysis
As of June 24, 2026, AbCellera Biologics Inc. (ABCL) trades at a price-to-earnings ratio of -11.5x, with a stock price of $5.63 and trailing twelve-month earnings per share of $-0.47.
The current P/E is 134% below its 5-year average of 34.2x. Over the past five years, ABCL's P/E has ranged from a low of 12.5x to a high of 106.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.0x, ABCL trades at a 152% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 196.5x.
Relative to the broader market, ABCL trades at a notable discount to the S&P 500 median P/E of 24.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABCL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABCL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ABCL P/E vs Peers
Drug Discovery and Antibody Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $64B | 14.9Lowest | 2.35 | +8% | |
| $8B | 27.2 | 1.18Best | -25% | |
| $38B | 123.7 | - | +207%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ABCL Historical P/E Data (2020–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Dec 31 2022 | $10.13 | $0.50 | 20.2x | -41% |
| FY2022 Q3 | Sep 30 2022 | $9.89 | $0.79 | 12.5x | -63% |
| FY2022 Q2 | - | $10.65 | $0.63 | 16.9x | -51% |
| FY2022 Q1 | - | $9.75 | $0.64 | 15.2x | -55% |
| FY2021 Q4 | Dec 31 2021 | $14.30 | $0.47 | 30.4x | -11% |
| FY2021 Q3 | - | $20.04 | $0.65 | 30.8x | -10% |
| FY2021 Q2 | Jun 30 2021 | $22.00 | $0.72 | 30.6x | -11% |
| FY2021 Q1 | Mar 31 2021 | $33.96 | $0.76 | 44.8x | +31% |
| FY2020 Q4 | - | $40.24 | $0.38 | 106.3x | +211% |
Average P/E for displayed period: 34.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABCL — Frequently Asked Questions
Quick answers to the most common questions about buying ABCL stock.
What is ABCL's P/E ratio?
AbCellera Biologics Inc. (ABCL) trailing twelve-month P/E ratio is -11.5x, based on TTM diluted EPS of $-0.47. The 5-year average P/E is 34.2x and the historical range spans 12.5x to 106.3x.
Is ABCL stock overvalued or undervalued?
ABCL trades at -11.5x P/E, below its 5-year average of 34.2x. At the 0th percentile of its historical range (12.5x–106.3x), the stock is priced at a discount to its own history.
Is ABCL stock expensive?
No, ABCL is not expensive on a historical basis. The current P/E of -11.5x is below the 5-year average of 34.2x and sits at the 0th percentile of its valuation range.
What is ABCL's historical P/E range?
Over the past 5 years, ABCL's P/E ratio has ranged from 12.5x to 106.3x, with a median of 30.4x and an average of 34.2x. The current P/E of -11.5x places the stock at the 0th percentile of this range. Full historical data spans 2020–2022.
How does ABCL's P/E compare to the S&P 500?
ABCL trades at -11.5x P/E versus the S&P 500 median of 24.6x. The 147% discount to the market suggests lower growth expectations or perceived higher risk.
How does ABCL's valuation compare to Healthcare peers?
AbCellera Biologics Inc. P/E of -11.5x compares to the Healthcare sector median of 22.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ABCL's PEG ratio?
ABCL PEG ratio is N/A, based on a P/E of -11.5x and EPS growth of 10.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ABCL's earnings yield?
ABCL earnings yield is N/A, the inverse of its -11.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.